Be the Match BioTherapies’ first ever equity investment was motivated by desire to back a company that shared its goal of helping transplant patients achieve better outcomes, rather than by a planned strategic shift toward...
Novartis AG (NYSE:NVS; SIX:NOVN) granted Magenta Therapeutics Inc. (Cambridge, Mass.) rights to MGTA-456 (formerly HSC835) in selected applications, including immune and blood diseases. The product comprises umbilical cord blood hematopoietic stem cells that have been...
Stem cell transplant company Magenta Therapeutics Inc. (Cambridge, Mass.) raised $50 million in an oversubscribed series B round led by GV. The company also announced separate partnerships with Novartis AG (NYSE:NVS; SIX;NOVN) and Be The...